Loading organizations...
§ Public · San Diego, CA, USA
A biopharmaceutical company developing neffy, an FDA-approved needle-free treatment for anaphylaxis and severe allergic reactions.
ARS Pharmaceuticals is a San Diego, California-based biopharmaceutical company developing needle-free treatments for severe allergic reactions and anaphylaxis. Formerly known as Silverback Therapeutics, the publicly traded enterprise operates under the NASDAQ ticker SPRY and focuses on commercializing neffy, an epinephrine nasal spray designed as an alternative to traditional auto-injectors. Following a previous Complete Response Letter requesting additional clinical study data, the United States Food and Drug Administration officially approved the drug in August 2024 for the emergency treatment of Type 1 allergic reactions in adults and older children. The commercial-stage firm has secured financial backing from notable institutional investors, including Deerfield Management and SR One, to directly compete against established market alternatives like the EpiPen. ARS Pharmaceuticals was originally founded in 2015 by three executive leaders: Richard Lowenthal, Sarina Tanimoto, and Robert Bell.
ARS Pharmaceuticals has raised $55.0M across 1 funding round.
ARS Pharmaceuticals has raised $55.0M in total across 1 funding round.
ARS Pharmaceuticals has raised $55.0M in total across 1 funding round.
ARS Pharmaceuticals's investors include SR One, Endeavor Venture Funds, FPV Fund, Krishna Yeshwant, MPM Capital, Qiming Venture Partners USA, Westlake Village BioPartners, Deerfield Management, Peter Kolchinsky.
ARS Pharmaceuticals has raised $55.0M across 1 funding round. Most recently, it raised $55.0M Series D in August 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 1, 2021 | $55M Series D | SR ONE | Endeavor Venture Funds, FPV Fund, Krishna Yeshwant, MPM Capital, Qiming Venture Partners USA, Westlake Village BioPartners, Deerfield Management, Peter Kolchinsky | Announced |
ARS Pharmaceuticals is a biopharmaceutical company, not a traditional technology company, focused on developing innovative treatments for allergic reactions.[1] Its lead product, neffy (previously ARS-1), is a needle-free nasal spray epinephrine designed as a potentially first-of-its-kind alternative to traditional auto-injectors like EpiPen for treating anaphylaxis.[1] The company serves patients with severe allergies, including those who struggle with needle-based delivery due to fear or usability issues, addressing the critical problem of rapid, accessible emergency treatment to prevent life-threatening reactions.[1]
Growth momentum has centered on advancing neffy through clinical development and regulatory milestones, positioning ARS Pharmaceuticals in the growing market for patient-friendly allergy therapies amid rising anaphylaxis cases.[1]
ARS Pharmaceuticals emerged in the biopharmaceutical space with a focus on proprietary delivery technologies for allergy treatments, though specific founding details like exact year or founders are not detailed in available profiles.[1][2] The company's idea stems from identifying gaps in current anaphylaxis treatments, leading to the development of neffy using novel ImmunoTAC technology for targeted immune modulation and needle-free administration.[2] Early traction likely built around neffy's potential as a disruptive product, gaining attention as a biotech innovator in allergy care.[1]
ARS Pharmaceuticals rides the trend of biotech advancements in drug delivery systems, particularly patient-centric innovations like needle-free alternatives amid increasing allergy prevalence driven by environmental and dietary factors.[1] Timing is favorable with regulatory interest in accessible epinephrine options and post-pandemic emphasis on home-based emergency care. Market forces include competition from legacy injectors and demand for easier-to-use devices, positioning the company to influence the allergy treatment ecosystem by expanding treatment adoption and potentially lowering barriers in underserved populations.[1][2]
Next steps likely involve neffy commercialization, FDA approvals, and partnerships to scale distribution, with trends like personalized medicine and digital health integrations shaping growth.[1] Influence may evolve by redefining anaphylaxis standards, boosting accessibility if neffy succeeds as a market leader—echoing its core mission to transform allergy emergency response from the ground up.[1][2]